US: +1 646-781-8004 | Europe:+44-203-868-8738 | APAC:+91-744-778-0008

 sales@meticulousresearch.com

RWE Oncology Market

Release date:

May-2022

Region:

global

Research Code:MRHC -104590

Sku:MRHC -104590

RWE Oncology Market by Component (Datasets [EHR, Claims, Cancer Registries], Consulting & Analytics Services), Application (Drug Development, Approval, Market Access, Post Market Surveillance), End User (Pharma, Payer, Provider) - Global Forecast to 2029

  • Report ID: MRHC -104590
  • Pages: 200
  • May-2022
  • Formats*: PDF
  • Category: Healthcare
  • Delivery: 24 to 72 Hours
COVID-19

This report provides pre & post COVID-19 market estimates.

The RWE Oncology Market is expected to grow at a CAGR of 14.2% from 2022–2029 to reach $1.65 billion by 2029. Real-world evidence (RWE) is clinical evidence gathered via RWD analysis on the use and potential benefits or risks of a medical product. RWE can be produced through various study designs or analyses, including but not limited to randomized trials, large simple trials, pragmatic trials, and observational studies (prospective or retrospective). RWE has several applications in oncology, including drug development life cycles, reducing development duration, reducing the costs of clinical trials, and improving the probability of technical and regulatory success. The growth of this market is driven by factors such as the rising prevalence of cancer, rapidly growing big data in healthcare, the shift from volume to value-based care, and the rising focus on personalized healthcare.

Impact of COVID-19 on the RWE Oncology Market

The outbreak of the COVID-19 pandemic exerted a tremendous burden on healthcare sectors worldwide. The RWE oncology solutions market experienced an initial market shrinkage due to the impacts of the COVID-19 pandemic. The market shrinkage was attributed to factors such as the restrictions imposed on travel in several countries, the shifting of resources toward COVID-19 treatments in healthcare settings (including cancer care settings), and limited access to hospitals that disrupted the delivery of oncology services, including delayed diagnosis & treatment and clinical trial interruptions. These factors affected the amount of real-world data generated globally. The unavailability of treatment, patients, and resources significantly impacted the cancer care sector.

However, after the initial market shrinkage, real-world evidence (RWE) is set to become the most influential emerging technology in cancer care. The FDA recognized the challenges posed by the COVID-19 pandemic to oncology trials. In September 2021, it issued a draft guidance on real-world data for evidence generation supporting regulatory decisions. This initiative promoted the adoption of RWE in clinical trials, and since then, RWD has been used increasingly in cancer progression mapping and patient profiling, clinical trials, drug development, post-market studies, treatment choice, dosing strategies, treatment sequencing, adverse event management, regulatory decision making, and financial burden associated with oncology treatment.

Thus, the COVID-19 pandemic negatively impacted the RWE oncology solutions market. However, RWD made a significant impact during the COVID-19 pandemic and continues to play a significant role in the treatment of cancer due to the initiatives taken by the FDA to promote RWE and support regulatory decision-making for drugs and biological products.

RWE Oncology Market

Click here to : Request Sample of this Report 

Key Findings in the RWE Oncology Market Study

Real-world Datasets Generated Larger Proportion of Revenue Compared to RWE Consulting & Analytics Services

In 2022, the real-world datasets segment is estimated to account for the larger share of the RWE oncology solutions market. The large market share of this segment is attributed to the growing amount of medical data generated in hospitals, increasing dependence on outcome-based studies on real-world data, and the rising demand for information regarding drug safety among payers, regulatory bodies, and providers.

Drug Development & Approvals Segment to Dominate the Market

In 2022, the drug development & approvals segment is estimated to account for the largest share of the RWE oncology solutions market. The large market share of this segment is attributed to the rising number of cancer cases, compelling pharmaceutical and biopharmaceutical companies to focus on drug development for cancer treatment. The effective deployment of RWE can significantly accelerate the pace of discovery, enable drug approvals, and help understand the impact of new oncology therapies, boosting the growth of this segment.

Pharmaceutical & Medical Device Companies Segment to Register Largest Share in the RWE Oncology Market by 2029.

The pharmaceutical & medical device companies segment is estimated to account for the largest share of the RWE solutions market in 2022. The large market share of this segment is attributed to the importance of RWE studies in cancer drug development & approvals and the growing need to avoid costly drug recalls and assess drug performance in real-world settings.

North America to Dominate the Market

In 2022, North America is estimated to account for the largest share of the RWE oncology solutions market, followed by Europe, Asia-Pacific, Latin America, and the Middle East & Africa. The high market growth in North America is attributed to the increasing number of cancer cases, stringent regulations for drug approvals, implementation of the 21st Century Cures Act, increased usage of electronic datasets, advanced healthcare industry, and the rising amount of big data in healthcare.

Additionally, the adoption of EHRs in hospitals and patient registries is boosting the RWE oncology solutions market in North America. Basic EHR adoption has increased since 2010 in the U.S., from 27.9% in 2010 to nearly 86% in 2017. As of 2021, 94% of the hospitals in the U.S. are in the process of adopting EHRs.

Key Players

The report includes a competitive landscape based on an extensive assessment of the key strategic developments of leading market participants over the past four years. The key players profiled in the RWE oncology solutions market report include IQVIA Holdings Inc.(U.S.), ICON plc (Ireland), PPD, Inc. (U.S.), SYNEOS HEALTH, INC. (U.S.), CLARIVATE PLC (U.S.), Medpace Holdings Inc. (U.S.), Symphony Innovation, LLC (U.S.), Clinigen Group plc (U.K.), Cognizant Technology Solutions Corporation (U.S.), Oracle Corporation (U.S.), PAREXEL International Corporation (U.S.), PerkinElmer, Inc. (U.S.), SAS Institute Inc. (U.S.), UnitedHealth Group Incorporated (U.S.), and Flatiron Health (U.S.).

Scope of the Report:

RWE Oncology Solutions Market, by Component

  • Real-world Datasets
    • Disparate Datasets
      • EMR/EHR/Clinical Data
      • Claims & Billing Data
      • Pharmacy Data
      • Cancer Registries
      • Other Disparate Datasets
    • Integrated Datasets
  • Real-world Consulting & Analytics Services

(Note: Other Disparate Datasets include data generated from mobile applications, wearable devices, and social media).

RWE Oncology Solutions Market, by Application

  • Drug Development & Approvals
  • Market Access & Reimbursement/Coverage Decisions
  • Post-market Surveillance
  • Medical Device Development & Approvals
  • Other Applications

(Note: Other Applications include regulatory and clinical decision-making).

RWE Oncology Solutions Market, by End User

  • Pharmaceutical, Biotechnology, and Medical Device Companies
  • Healthcare Payers
  • Healthcare Providers
  • Other End Users

(Note: Other end users include academic research institutions, patient advocacy groups, regulators, and health technology assessment agencies).

RWE Oncology Solutions Market, by Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Spain
    • Rest of Europe (RoE)
  • Asia-Pacific (APAC)
    • Japan
    • China
    • India
    • South Korea
    • Taiwan
    • Singapore
    • Rest of APAC (RoAPAC)
  • Latin America
  • Middle East & Africa

Key questions answered in the report:

What is the focus of the RWE oncology solutions market study?

The RWE oncology solutions market study covers the market sizes and forecasts for various real-world evidence oncology solutions offered by key market players. These solutions are utilized to support pharmaceutical, biotechnology & medical device companies, healthcare payers, healthcare providers, and other end users in making key decisions related to drug development & approvals, medical device development & approvals, market access & reimbursement/coverage decisions, post-market surveillance. The RWE oncology solutions market study provided in this report involves the value analysis of various segments and subsegments of RWE oncology solutions providers at the regional and country levels.

What is the value of revenue generated from the sales of RWE oncology solutions across the globe? At what rate is their demand expected to grow for the next 5–7 years?

The global RWE oncology solutions market is projected to reach $1.65 billion by 2029, at a CAGR of 14.2% during the forecast period.

Which component type is estimated to hold the major share of the market?

Based on component, in 2022, the real-world datasets segment is estimated to account for the larger share of the RWE oncology solutions market. The large market share of this segment is attributed to the growing amount of medical data generated in hospitals, increasing dependence on outcome-based studies on real-world data, and the rising demand for information regarding drug safety among payers, regulatory bodies, and providers.

Which application segment of the market is projected to create more traction in the RWE oncology solutions market?

Based on application, in 2022, the drug development & approvals segment is estimated to account for the largest share of the RWE oncology solutions market. The large market share of this segment is attributed to the rising number of cancer cases, compelling pharmaceutical and biopharmaceutical companies to focus on drug development for cancer treatment. The effective deployment of RWE can significantly accelerate the pace of discovery, enable drug approvals, and help understand the impact of new oncology therapies, boosting the growth of this segment.

What are the key factors supporting the growth of this market? What are the major opportunities for existing market players and new entrants in the RWE oncology solutions market?

The growth of this market is driven by factors such as the rising prevalence of cancer, rapidly growing big data in healthcare, the shift from volume to value-based care, and the rising focus on personalized healthcare. Furthermore, emerging markets, rising focus on end-to-end RWE services, and rising adoption of mobile applications and wearable devices and AI in RWE are expected to provide significant growth opportunities for market players and new entrants in this market.

Who are the major players operating in the RWE oncology solutions market?

The key companies operating in the RWE oncology solutions market include IQVIA Holdings Inc. (U.S.), ICON plc (Ireland), PPD, Inc. (U.S.), SYNEOS HEALTH, INC. (U.S.), CLARIVATE PLC (U.S.), Medpace Holdings Inc. (U.S.), Symphony Innovation, LLC (U.S.), Clinigen Group plc (U.K.), Cognizant Technology Solutions Corporation (U.S.), Oracle Corporation (U.S.), PAREXEL International Corporation (U.S.), PerkinElmer, Inc. (U.S.), SAS Institute Inc. (U.S.), UnitedHealth Group Incorporated (U.S.), and Flatiron Health (U.S.).

Which regions/countries are expected to offer significant growth opportunities for the companies operating in the RWE solutions market?

Emerging economies from Asia, such as Japan and China, are projected to offer significant growth opportunities for companies operating in this market. The increasing demand for data defining the value and effectiveness of medicines by payers, the high demand for conducting real-world studies in drug R&D, and increasing government interest in using real-world studies for regulatory decision-making are the factors expected to offer growth opportunities for market players in this region.

1.    Introduction 
       1.1.    Market Definition 
       1.2.    Market Ecosystem 
       1.3.    Currency 

2.    Research Methodology 
       2.1.    Research Process 
       2.2.    Data Collection & Validation 
                 2.2.1.    Secondary Research 
                 2.2.2.    Primary Research 
       2.3.    Market Assessment 
                 2.3.1.    Market Size Estimation 
                              2.3.1.1.    Bottom-up Approach 
                              2.3.1.2.    Top-down Approach
                              2.3.1.3.    Growth Forecast
                 2.3.2.    Market Share Analysis

3.    Executive Summary 

4.    Market Insights 
       4.1.    Market Overview 
       4.2.    Drivers 
                 4.2.1.    Growing Burden of Cancer
                 4.2.2.    Rising Focus Towards Personalized Healthcare 
                 4.2.3.    Delays in Drug Development and the Subsequent Increase in Development Costs 
                 4.2.4.    Shift Towards Value-based Care 
                 4.2.5.    Rapidly Growing Big Data in Healthcare 
       4.3.    Restraints 
                 4.3.1.    Reluctance to Rely on Real-world Studies 
       4.4.    Opportunities 
                 4.4.1.    Emerging Economies 
                 4.4.2.    Rising Focus on End-to-end RWE Services 
                 4.4.3.    Rising Adoption of Wearable Devices, Mobile Apps, and Artificial Intelligence in RWE 
       4.5.    Challenges 
                 4.5.1.    Lack of Standardized Methodologies to Develop RWE 
       4.6.    Impact Assessment of COVID-19 
       4.7.    Key Market Trends 
                 4.7.1.    Growing Adoption of RWE in Drug Development and Commercialization 
                 4.7.2.    Rising Number of Consolidations 
                 4.7.3.    Improved Patient Outcomes and value Creation from Real-world Evidence 

5.   Regulatory Analysis— Real-world Evidence (RWE) Oncology Solutions Market 
      5.1.    Introduction 
      5.2.    North America 
      5.3.    Europe 
      5.4.    Asia-Pacific 
      5.5.    Rest of the World 

6.   Pricing Models (EMR/Genomic/Integrated Datasets) 
      6.1.    Introduction 
      6.2.    Pay Per Patient Record (Volume-based Pricing) 
      6.3.    Pay Per Usage (Value-based Pricing) 
      6.4.    Annual Subscription 

7.   Global RWE Oncology Solutions Market, by Component 
      7.1.    Introduction 
      7.2.    Datasets 
                 7.2.1.    Disparate Datasets 
                              7.2.1.1.    EMR/EHR/Clinical Data 
                              7.2.1.2.    Claims & Billing Data 
                              7.2.1.3.    Pharmacy Data 
                              7.2.1.4.    Cancer Registries 
                              7.2.1.5.    Other Disparate Datasets 
                 7.2.2.    Integrated Datasets 
       7.3.    Consulting Services 

8.   Global RWE Oncology Solutions Market, by Application 
      8.1.    Introduction
      8.2.    Drug Development & Approvals
      8.3.    Market Access & Reimbursement/Coverage Decisions  
      8.4.    Medical Device Development & Approvals 
      8.5.    Post-market Surveillance 
      8.6.    Other Applications 

9.   Global RWE Oncology Solutions Market, by End User 
      9.1.    Introduction 
      9.2.    Pharmaceutical, Biotechnology, and Medical Device Companies 
      9.3.    Healthcare Payers 
      9.4.    Healthcare Providers 
      9.5.    Other End Users 

10.   RWE Oncology Solutions Market, by Geography 
        10.1.    Introduction 
        10.2.    North America
                   10.2.1.    U.S. 
                   10.2.2.    Canada 
        10.3.    Europe 
                   10.3.1.    U.K. 
                   10.3.2.    Germany 
                   10.3.3.    France 
                   10.3.4.    Italy 
                   10.3.5.    Spain 
        10.4.    Asia-Pacific 
                   10.4.1.    Japan 
                   10.4.2.    China 
                   10.4.3.    India 
                   10.4.4.    South Korea 
                   10.4.5.    Taiwan 
                   10.4.6.    Singapore 
                   10.4.7.    Rest of Asia-Pacific 
        10.5.    Latin America 
        10.6.    Middle East & Africa 

11.   Competitive Landscape     
        11.1.    Introduction 
        11.2.    Key Growth Strategies 
        11.3.    Competitive Benchmarking 
        11.4.    Market Share Analysis (2020) 
                   11.4.1.    IQVIA Holdings, Inc. (U.S.) 
                   11.4.2.    ICON plc (Ireland) 
                   11.4.3.    PPD, Inc. 

12.   Company Profiles 
        12.1.    IQVIA HOLDINGS INC. 
        12.2.    PPD, Inc. 
        12.3.    ICON plc 
        12.4.    Parexel International Corporation 
        12.5.    IBM CORPORATION 
        12.6.    UnitedHealth Group Incorporated 
        12.7.    Flatiron Health 
        12.8.    ORACLE CORPORATION 
        12.9.    SAS Institute, Inc. 
        12.10.    Anthem, Inc. 
        12.11.    Clinigen Group plc 
        12.12.    Cognizant Technology Solutions Corporation 
        12.13.    PerkinElmer, Inc. 

13.   Appendix 
        13.1.    Questionnaire 
        13.2.    Available Customization

LIST OF TABLES

Table 1    Global RWE Oncology Solutions Market Drivers: Impact Analysis (2021–2028) 
Table 2    Number of Persons Aged 65 Years or Over, by Region (2019 Vs. 2050) 
Table 3    Total Per-study Cost (In USD Million), by Phase and Therapeutic Area 
Table 4    Sources of Healthcare Data 
Table 5    Global RWE Oncology Market Restraints: Impact Analysis (2021–2028) 
Table 6    RWE in Latin American Countries 
Table 7    Observed Indicative Prices of Real-World Data by Type (USD Per Patient Record) 
Table 8    Global RWE Oncology Solutions Market Size, by Component, 2019–2029 (USD Million) 
Table 9    Global Real-world Evidence Oncology Datasets Market Size, by Type, 2019–2029 (USD Million) 
Table 10    Real-world Evidence Oncology Datasets Market Size, by Country/Region, 2019–2029 (USD Million) 
Table 11    Global RWE Oncology Disparate Datasets Market Size, by Type, 2019–2029 (USD Million) 
Table 12    RWE Oncology Disparate Datasets Market Size, by Country/Region, 2019–2029 (USD Million) 
Table 13    RWE Oncology EMR/EHR/Clinical Data Market Size, by Country/Region, 2019–2029 (USD Million) 
Table 14    RWE Oncology Claims & Billing Data Market Size, by Country/Region, 2019–2029 (USD Million) 
Table 15    RWE Oncology Pharmacy Data Market Size, by Country/Region, 2019–2029 (USD Million) 
Table 16    RWE Cancer Registries Data Market Size, by Country/Region, 2019–2029 (USD Million) 
Table 17    Other RWE Oncology Disparate Datasets Market Size, by Country/Region, 2019–2029 (USD Million) 
Table 18    RWE Oncology Integrated Datasets Market Size, by Country/Region, 2019–2029 (USD Million) 
Table 19    RWE Oncology Consulting Services Market Size, by Country/Region, 2019–2029 (USD Million) 
Table 20    Global RWE Oncology Solutions Market Size, by Application, 2019–2029 (USD Million) 
Table 21    Global RWE Oncology Solutions Market Size for Market Access & Reimbursement/Coverage Decisions, by Country/Region, 2019–2029 (USD Million) 
Table 22    Oncology: Drugs in the R&D Pipeline 
Table 23    Global RWE Oncology Solutions Market Size for Drug Development & Approvals, by Country/Region, 2019–2029 (USD Million) 
Table 24    Global RWE Oncology Solutions Market Size for Medical Device Development & Approvals, by Country/Region, 2019–2029 (USD Million) 
Table 25    Global RWE Oncology Solutions Market Size for Post-Market Surveillance, by Country/ Region, 2019–2029 (USD Million) 
Table 26    Global RWE Oncology Solutions Market Size for Other Applications, by Country/Region, 2019–2029 (USD Million) 
Table 27    Global RWE Oncology Solutions Market Size, by End User, 2019–2029 (USD Million) 
Table 28    Global RWE Oncology Solutions Market Size for Pharmaceutical, Biotechnology, and Medical Device Companies, by Country/Region, 2019–2029 (USD Million) 
Table 29    Global RWE Oncology Market Size for Healthcare Payers, by Country/Region, 2019–2029 (USD Million) 
Table 30    Global RWE Oncology Solutions Market Size for Healthcare Providers, by Country/Region, 2019–2029 (USD Million) 
Table 31    Global RWE Oncology Market Size for Other End Users, by Country/Region, 2019–2029 (USD Million) 
Table 32    Global RWE Oncology Solutions Market Size, by Country/Region, 2020–2029 (USD Million) 
Table 33    North America: RWE Oncology Solutions Market Size, by Country, 2020–2029 (USD Million) 
Table 34    North America: RWE Oncology Solutions Market Size, by Component, 2020–2029 (USD Million) 
Table 35    North America: RWE Oncology Datasets Market Size, by Type, 2020–2029 (USD Million) 
Table 36    North America: RWE Oncology Disparate Datasets Market Size, by Type, 2020–2029 (USD Million) 
Table 37    North America: RWE Oncology Solutions Market Size, by Application, 2020–2029 (USD Million) 
Table 38    North America: RWE Oncology Solutions Market Size, by End User, 2020–2029 (USD Million) 
Table 39    U.S.: Estimated Number of New Cancer Cases (2021–2022) 
Table 40    U.S.: RWE Oncology Solutions Market Size, by Component, 2020–2029 (USD Million) 
Table 41    U.S.: RWE Datasets Market Size, by Type, 2020–2029 (USD Million) 
Table 42    U.S.: RWE Disparate Datasets Market Size, by Type, 2020–2029 (USD Million) 
Table 43    U.S.: RWE Oncology Solutions Market Size, by Application, 2020–2029 (USD Million) 
Table 44    U.S.: RWE Solutions Market Size, by End User, 2020–2029 (USD Million) 
Table 45    Canada: RWE Oncology Solutions Market Size, by Component, 2020–2029 (USD Million) 
Table 46    Canada: RWE Datasets Market Size, by Type, 2020–2029 (USD Million) 
Table 47    Canada: RWE Disparate Datasets Market Size, by Type, 2020–2029 (USD Million) 
Table 48    Canada: RWE Oncology Solutions Market Size, by Application, 2020–2029 (USD Million) 
Table 49    Canada: RWE Oncology Market Size, by End User, 2020–2029 (USD Million) 
Table 50    Europe: RWE Oncology Solutions Market Size, by Country, 2019–2029 (USD Million) 
Table 51    Europe: RWE Oncology Solutions Market Size, by Component, 2020–2029 (USD Million) 
Table 52    Europe: RWE Oncology Datasets Market Size, by Type, 2020–2029 (USD Million) 
Table 53    Europe: RWE Oncology Solutions Disparate Datasets Market Size, by Type, 2020–2029 (USD Million) 
Table 54    Europe: RWE Oncology Solutions Market Size, by Application, 2020–2029 (USD Million) 
Table 55    Europe: RWE Oncology Solutions Market Size, by End User, 2020–2029 (USD Million) 
Table 56    U.K.: Conferences and Workshops on Real-world Evidence Solutions 
Table 57    U.K.: RWE Oncology Solutions Market Size, by Component, 2020–2029 (USD Million) 
Table 58    U.K.: RWE Oncology Datasets Market Size, by Type, 2020–2029 (USD Million) 
Table 59    U.K.: RWE Oncology Solutions Disparate Datasets Market Size, by Type, 2020–2029 (USD Million) 
Table 60    U.K.: RWE Oncology Solutions Market Size, by Application, 2020–2029 (USD Million) 
Table 61    U.K.: RWE Oncology Solutions Market Size, by End User, 2020–2029 (USD Million) 
Table 62    Conferences, Symposia, and Workshops in Germany 
Table 63    Germany: RWE Oncology Solutions Market Size, by Component, 2020–2029 (USD Million) 
Table 64    Germany: RWE Oncology Solutions Datasets Market Size, by Type, 2020–2029 (USD Million) 
Table 65    Germany: RWE Oncology Solutions Disparate Datasets Market Size, by Type, 2020–2029 (USD Million) 
Table 66    Germany: RWE Oncology Solutions Market Size, by Application, 2020–2029 (USD Million) 
Table 67    Germany: RWE Oncology Solutions Market Size, by End User, 2020–2029 (USD Million) 
Table 68    France: RWE Oncology Solutions Market Size, by Component, 2020–2029 (USD Million) 
Table 69    France: RWE Oncology Solutions Datasets Market Size, by Type, 2020–2029 (USD Million) 
Table 70    France: RWE Oncology Solutions Disparate Datasets Market Size, by Type, 2020–2029 (USD Million) 
Table 71    France: RWE Oncology Solutions Market Size, by Application, 2020–2029 (USD Million) 
Table 72    France: RWE Oncology Solutions Market Size, by End User, 2020–2029 (USD Million) 
Table 73    Italy: RWE Oncology Solutions Market Size, by Component, 2020–2029 (USD Million) 
Table 74    Italy: RWE Oncology Solutions Datasets Market Size, by Type, 2020–2029 (USD Million) 
Table 75    Italy: RWE Oncology Solutions Disparate Datasets Market Size, by Type, 2020–2029 (USD Million) 
Table 76    Italy: RWE Oncology Market Size, by Application, 2020–2029 (USD Million) 
Table 77    Italy: RWE Oncology Solutions Market Size, by End User, 2020–2029 (USD Million) 
Table 78    Spain: RWE Oncology Market Size, by Component, 2020–2029 (USD Million) 
Table 79    Spain: RWE Oncology Solutions Datasets Market Size, by Type, 2020–2029 (USD Million) 
Table 80    Spain: RWE Oncology Solutions Disparate Datasets Market Size, by Type, 2020–2029 (USD Million) 
Table 81    Spain: RWE Oncology Solutions Market Size, by Application, 2020–2029 (USD Million) 
Table 82    Spain: RWE Oncology Solutions Market Size, by End User, 2020–2029 (USD Million) 
Table 83    RoE: RWE Oncology Solutions Market Size, by Component, 2020–2029 (USD Million) 
Table 84    RoE: RWE Oncology Solutions Datasets Market Size, by Type, 2020–2029 (USD Million) 
Table 85    RoE: RWE Oncology Solutions Disparate Datasets Market Size, by Type, 2020–2029 (USD Million) 
Table 86    RoE: RWE Oncology Solutions Market Size, by Application, 2020–2029 (USD Million) 
Table 87    RoE: RWE Oncology Solutions Market Size, by End User, 2020–2029 (USD Million) 
Table 88    Latin America: RWE Oncology Solutions Market Size, by Component, 2020–2029 (USD Million) 
Table 89    Latin America: RWE Oncology Solutions Datasets Market Size, by Type, 2020–2029 (USD Million) 
Table 90    Latin America: RWE Oncology Solutions Disparate Datasets Market Size, by Type, 2020–2029 (USD Million) 
Table 91    Latin America: RWE Oncology Solutions Market Size, by Application, 2020–2029 (USD Million) 
Table 92    Latin America: RWE Oncology Solutions Market Size, by End User, 2020–2029 (USD Million) 
Table 93    Middle East & Africa: RWE Oncology Solutions Market Size, by Component, 2020–2029 (USD Million) 
Table 94     Middle East & Africa: RWE Oncology Solutions Datasets Market Size, by Type, 2020–2029 (USD Million) 
Table 95    Middle East & Africa: RWE Oncology Solutions Disparate Datasets Market Size, by Type, 2020–2029 (USD Million) 
Table 96    Middle East & Africa: RWE Oncology Solutions Market Size, by Application, 2020–2029 (USD Million) 
Table 97    Middle East & Africa: RWE Oncology Solutions Market Size, by End User, 2020–2029 (USD Million) 
Table 98    Recent Developments, by Company, 2018–2021 

LIST OF FIGURES

Figure 1    Key Stakeholders 
Figure 2    Research Process 
Figure 3    Key Secondary Sources 
Figure 4    Primary Research Techniques
Figure 5    Key Executives Interviewed 
Figure 6    Breakdown of Primary Interviews (Supply-side & Demand-Side) 
Figure 7    Market Size Estimation
Figure 8    Global RWE Oncology Solutions Market, by Component, 2022 Vs. 2029 (USD Million) 
Figure 9    Global RWE Oncology Solutions Market, by Application, 2022 Vs. 2029 (USD Million) 
Figure 10    Global RWE Oncology Solutions Market, by End User, 2022 Vs. 2029 (USD Million) 
Figure 11    RWE Oncology Solutions Market, by Geography 
Figure 12    Market Dynamics 
Figure 13    Number of People with Chronic Conditions in the U.S. (2000-2030) 
Figure 14    Percentage of Personalized Medicines Approved (2015-2020) 
Figure 15    Asia-Pacific: Percent Share of Global Clinical Trial Activity (2012-2020) 
Figure 16    Global RWE Oncology Solutions Market Size, by Component, 2022–2029 (USD Million) 
Figure 17    U.S.: Number of E-Prescriptions, 2013–2020 (Billions) 
Figure 18    Global RWE Oncology Solutions Market Size, by Application, 2022–2029 (USD Million) 
Figure 19    Estimated Number of New Cancer Cases, by Region, 2020–2040 (In Millions) 
Figure 20    Global RWE Oncology Solutions Market Size, by End User, 2022–2029 (USD Million) 
Figure 21    Proportion of the Pharmaceutical Pipeline Which is in Development for Cancer, 2010–2021 
Figure 22    Global RWE Oncology Solutions Market, by Region, 2022–2029 (USD Million) 
Figure 23    North America: RWE Oncology Solutions Market Snapshot 
Figure 24    Europe: RWE Oncology Solutions Market Snapshot 
Figure 25    France: Share of Population Aged 65 & Above, 2010–2020 
Figure 26    Italy: Share of Population Aged 65 Years & Above, 2015–2020 
Figure 27    Key Growth Strategies Adopted by Leading Players (2018–2021) 
Figure 28    Real-world Evidence Oncology Solutions: Competitive Benchmarking 
Figure 29    Market Share Analysis: Real-world Evidence Oncology Solutions Industry (2021) 
Figure 30    IQVIA HOLDINGS INC.: Financial Overview
Figure 31    PPD, Inc.: Financial Overview
Figure 32    ICON plc: Financial Overview
Figure 33    IBM corporation: Financial Overview
Figure 34    UnitedHealth Group Incorporated: Financial Overview
Figure 35    Oracle Corporation: Financial Overview
Figure 36    Anthem, Inc.: Financial Overview
Figure 37    Clinigen Group plc: Financial Overview
Figure 38    Cognizant Technology Solutions Corporation: Financial Overview
Figure 39    PerkinElmer, Inc.: Financial Overview

 
Name can only consist of alphabets.
Please provide your full name.
 
Please provide valid email address.
Please provide your email address.
 
Please provide your job title.
 
Please provide your company name.
 
Please provide your company name.
 
Please provide valid phone number.
Please provide your phone number.
 
Please enter minimum 10 characters.
 
Please enter Captcha.
Please enter valid Captcha.

This website is secure and we do not share your personal information with any third party. Privacy Policy

Related Research

The RWE Oncology Market is expected to grow at a CAGR of 14.2% from 2022–2029 to reach $1.65 billion by 2029. Real-world evidence (RWE) is clinical evidence gathered via RWD analysis on the use and potential benefits or risks of a medical product. RWE can be produced through various study designs or analyses, including but not limited to randomized trials, large simple trials, pragmatic trials, and observational studies (prospective or retrospective). RWE has several applications in oncology, including drug development life cycles, reducing development duration, reducing the costs of clinical trials, and improving the probability of technical and regulatory success. The growth of this market is driven by factors such as the rising prevalence of cancer, rapidly growing big data in healthcare, the shift from volume to value-based care, and the rising focus on personalized healthcare.

Impact of COVID-19 on the RWE Oncology Market

The outbreak of the COVID-19 pandemic exerted a tremendous burden on healthcare sectors worldwide. The RWE oncology solutions market experienced an initial market shrinkage due to the impacts of the COVID-19 pandemic. The market shrinkage was attributed to factors such as the restrictions imposed on travel in several countries, the shifting of resources toward COVID-19 treatments in healthcare settings (including cancer care settings), and limited access to hospitals that disrupted the delivery of oncology services, including delayed diagnosis & treatment and clinical trial interruptions. These factors affected the amount of real-world data generated globally. The unavailability of treatment, patients, and resources significantly impacted the cancer care sector.

However, after the initial market shrinkage, real-world evidence (RWE) is set to become the most influential emerging technology in cancer care. The FDA recognized the challenges posed by the COVID-19 pandemic to oncology trials. In September 2021, it issued a draft guidance on real-world data for evidence generation supporting regulatory decisions. This initiative promoted the adoption of RWE in clinical trials, and since then, RWD has been used increasingly in cancer progression mapping and patient profiling, clinical trials, drug development, post-market studies, treatment choice, dosing strategies, treatment sequencing, adverse event management, regulatory decision making, and financial burden associated with oncology treatment.

Thus, the COVID-19 pandemic negatively impacted the RWE oncology solutions market. However, RWD made a significant impact during the COVID-19 pandemic and continues to play a significant role in the treatment of cancer due to the initiatives taken by the FDA to promote RWE and support regulatory decision-making for drugs and biological products.

RWE Oncology Market

Click here to : Request Sample of this Report 

Key Findings in the RWE Oncology Market Study

Real-world Datasets Generated Larger Proportion of Revenue Compared to RWE Consulting & Analytics Services

In 2022, the real-world datasets segment is estimated to account for the larger share of the RWE oncology solutions market. The large market share of this segment is attributed to the growing amount of medical data generated in hospitals, increasing dependence on outcome-based studies on real-world data, and the rising demand for information regarding drug safety among payers, regulatory bodies, and providers.

Drug Development & Approvals Segment to Dominate the Market

In 2022, the drug development & approvals segment is estimated to account for the largest share of the RWE oncology solutions market. The large market share of this segment is attributed to the rising number of cancer cases, compelling pharmaceutical and biopharmaceutical companies to focus on drug development for cancer treatment. The effective deployment of RWE can significantly accelerate the pace of discovery, enable drug approvals, and help understand the impact of new oncology therapies, boosting the growth of this segment.

Pharmaceutical & Medical Device Companies Segment to Register Largest Share in the RWE Oncology Market by 2029.

The pharmaceutical & medical device companies segment is estimated to account for the largest share of the RWE solutions market in 2022. The large market share of this segment is attributed to the importance of RWE studies in cancer drug development & approvals and the growing need to avoid costly drug recalls and assess drug performance in real-world settings.

North America to Dominate the Market

In 2022, North America is estimated to account for the largest share of the RWE oncology solutions market, followed by Europe, Asia-Pacific, Latin America, and the Middle East & Africa. The high market growth in North America is attributed to the increasing number of cancer cases, stringent regulations for drug approvals, implementation of the 21st Century Cures Act, increased usage of electronic datasets, advanced healthcare industry, and the rising amount of big data in healthcare.

Additionally, the adoption of EHRs in hospitals and patient registries is boosting the RWE oncology solutions market in North America. Basic EHR adoption has increased since 2010 in the U.S., from 27.9% in 2010 to nearly 86% in 2017. As of 2021, 94% of the hospitals in the U.S. are in the process of adopting EHRs.

Key Players

The report includes a competitive landscape based on an extensive assessment of the key strategic developments of leading market participants over the past four years. The key players profiled in the RWE oncology solutions market report include IQVIA Holdings Inc.(U.S.), ICON plc (Ireland), PPD, Inc. (U.S.), SYNEOS HEALTH, INC. (U.S.), CLARIVATE PLC (U.S.), Medpace Holdings Inc. (U.S.), Symphony Innovation, LLC (U.S.), Clinigen Group plc (U.K.), Cognizant Technology Solutions Corporation (U.S.), Oracle Corporation (U.S.), PAREXEL International Corporation (U.S.), PerkinElmer, Inc. (U.S.), SAS Institute Inc. (U.S.), UnitedHealth Group Incorporated (U.S.), and Flatiron Health (U.S.).

Scope of the Report:

RWE Oncology Solutions Market, by Component

  • Real-world Datasets
    • Disparate Datasets
      • EMR/EHR/Clinical Data
      • Claims & Billing Data
      • Pharmacy Data
      • Cancer Registries
      • Other Disparate Datasets
    • Integrated Datasets
  • Real-world Consulting & Analytics Services

(Note: Other Disparate Datasets include data generated from mobile applications, wearable devices, and social media).

RWE Oncology Solutions Market, by Application

  • Drug Development & Approvals
  • Market Access & Reimbursement/Coverage Decisions
  • Post-market Surveillance
  • Medical Device Development & Approvals
  • Other Applications

(Note: Other Applications include regulatory and clinical decision-making).

RWE Oncology Solutions Market, by End User

  • Pharmaceutical, Biotechnology, and Medical Device Companies
  • Healthcare Payers
  • Healthcare Providers
  • Other End Users

(Note: Other end users include academic research institutions, patient advocacy groups, regulators, and health technology assessment agencies).

RWE Oncology Solutions Market, by Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Spain
    • Rest of Europe (RoE)
  • Asia-Pacific (APAC)
    • Japan
    • China
    • India
    • South Korea
    • Taiwan
    • Singapore
    • Rest of APAC (RoAPAC)
  • Latin America
  • Middle East & Africa

Key questions answered in the report:

  Request Sample

1.    Introduction 
       1.1.    Market Definition 
       1.2.    Market Ecosystem 
       1.3.    Currency 

2.    Research Methodology 
       2.1.    Research Process 
       2.2.    Data Collection & Validation 
                 2.2.1.    Secondary Research 
                 2.2.2.    Primary Research 
       2.3.    Market Assessment 
                 2.3.1.    Market Size Estimation 
                              2.3.1.1.    Bottom-up Approach 
                              2.3.1.2.    Top-down Approach
                              2.3.1.3.    Growth Forecast
                 2.3.2.    Market Share Analysis

3.    Executive Summary 

4.    Market Insights 
       4.1.    Market Overview 
       4.2.    Drivers 
                 4.2.1.    Growing Burden of Cancer
                 4.2.2.    Rising Focus Towards Personalized Healthcare 
                 4.2.3.    Delays in Drug Development and the Subsequent Increase in Development Costs 
                 4.2.4.    Shift Towards Value-based Care 
                 4.2.5.    Rapidly Growing Big Data in Healthcare 
       4.3.    Restraints 
                 4.3.1.    Reluctance to Rely on Real-world Studies 
       4.4.    Opportunities 
                 4.4.1.    Emerging Economies 
                 4.4.2.    Rising Focus on End-to-end RWE Services 
                 4.4.3.    Rising Adoption of Wearable Devices, Mobile Apps, and Artificial Intelligence in RWE 
       4.5.    Challenges 
                 4.5.1.    Lack of Standardized Methodologies to Develop RWE 
       4.6.    Impact Assessment of COVID-19 
       4.7.    Key Market Trends 
                 4.7.1.    Growing Adoption of RWE in Drug Development and Commercialization 
                 4.7.2.    Rising Number of Consolidations 
                 4.7.3.    Improved Patient Outcomes and value Creation from Real-world Evidence 

5.   Regulatory Analysis— Real-world Evidence (RWE) Oncology Solutions Market 
      5.1.    Introduction 
      5.2.    North America 
      5.3.    Europe 
      5.4.    Asia-Pacific 
      5.5.    Rest of the World 

6.   Pricing Models (EMR/Genomic/Integrated Datasets) 
      6.1.    Introduction 
      6.2.    Pay Per Patient Record (Volume-based Pricing) 
      6.3.    Pay Per Usage (Value-based Pricing) 
      6.4.    Annual Subscription 

7.   Global RWE Oncology Solutions Market, by Component 
      7.1.    Introduction 
      7.2.    Datasets 
                 7.2.1.    Disparate Datasets 
                              7.2.1.1.    EMR/EHR/Clinical Data 
                              7.2.1.2.    Claims & Billing Data 
                              7.2.1.3.    Pharmacy Data 
                              7.2.1.4.    Cancer Registries 
                              7.2.1.5.    Other Disparate Datasets 
                 7.2.2.    Integrated Datasets 
       7.3.    Consulting Services 

8.   Global RWE Oncology Solutions Market, by Application 
      8.1.    Introduction
      8.2.    Drug Development & Approvals
      8.3.    Market Access & Reimbursement/Coverage Decisions  
      8.4.    Medical Device Development & Approvals 
      8.5.    Post-market Surveillance 
      8.6.    Other Applications 

9.   Global RWE Oncology Solutions Market, by End User 
      9.1.    Introduction 
      9.2.    Pharmaceutical, Biotechnology, and Medical Device Companies 
      9.3.    Healthcare Payers 
      9.4.    Healthcare Providers 
      9.5.    Other End Users 

10.   RWE Oncology Solutions Market, by Geography 
        10.1.    Introduction 
        10.2.    North America
                   10.2.1.    U.S. 
                   10.2.2.    Canada 
        10.3.    Europe 
                   10.3.1.    U.K. 
                   10.3.2.    Germany 
                   10.3.3.    France 
                   10.3.4.    Italy 
                   10.3.5.    Spain 
        10.4.    Asia-Pacific 
                   10.4.1.    Japan 
                   10.4.2.    China 
                   10.4.3.    India 
                   10.4.4.    South Korea 
                   10.4.5.    Taiwan 
                   10.4.6.    Singapore 
                   10.4.7.    Rest of Asia-Pacific 
        10.5.    Latin America 
        10.6.    Middle East & Africa 

11.   Competitive Landscape     
        11.1.    Introduction 
        11.2.    Key Growth Strategies 
        11.3.    Competitive Benchmarking 
        11.4.    Market Share Analysis (2020) 
                   11.4.1.    IQVIA Holdings, Inc. (U.S.) 
                   11.4.2.    ICON plc (Ireland) 
                   11.4.3.    PPD, Inc. 

12.   Company Profiles 
        12.1.    IQVIA HOLDINGS INC. 
        12.2.    PPD, Inc. 
        12.3.    ICON plc 
        12.4.    Parexel International Corporation 
        12.5.    IBM CORPORATION 
        12.6.    UnitedHealth Group Incorporated 
        12.7.    Flatiron Health 
        12.8.    ORACLE CORPORATION 
        12.9.    SAS Institute, Inc. 
        12.10.    Anthem, Inc. 
        12.11.    Clinigen Group plc 
        12.12.    Cognizant Technology Solutions Corporation 
        12.13.    PerkinElmer, Inc. 

13.   Appendix 
        13.1.    Questionnaire 
        13.2.    Available Customization

LIST OF TABLES

Table 1    Global RWE Oncology Solutions Market Drivers: Impact Analysis (2021–2028) 
Table 2    Number of Persons Aged 65 Years or Over, by Region (2019 Vs. 2050) 
Table 3    Total Per-study Cost (In USD Million), by Phase and Therapeutic Area 
Table 4    Sources of Healthcare Data 
Table 5    Global RWE Oncology Market Restraints: Impact Analysis (2021–2028) 
Table 6    RWE in Latin American Countries 
Table 7    Observed Indicative Prices of Real-World Data by Type (USD Per Patient Record) 
Table 8    Global RWE Oncology Solutions Market Size, by Component, 2019–2029 (USD Million) 
Table 9    Global Real-world Evidence Oncology Datasets Market Size, by Type, 2019–2029 (USD Million) 
Table 10    Real-world Evidence Oncology Datasets Market Size, by Country/Region, 2019–2029 (USD Million) 
Table 11    Global RWE Oncology Disparate Datasets Market Size, by Type, 2019–2029 (USD Million) 
Table 12    RWE Oncology Disparate Datasets Market Size, by Country/Region, 2019–2029 (USD Million) 
Table 13    RWE Oncology EMR/EHR/Clinical Data Market Size, by Country/Region, 2019–2029 (USD Million) 
Table 14    RWE Oncology Claims & Billing Data Market Size, by Country/Region, 2019–2029 (USD Million) 
Table 15    RWE Oncology Pharmacy Data Market Size, by Country/Region, 2019–2029 (USD Million) 
Table 16    RWE Cancer Registries Data Market Size, by Country/Region, 2019–2029 (USD Million) 
Table 17    Other RWE Oncology Disparate Datasets Market Size, by Country/Region, 2019–2029 (USD Million) 
Table 18    RWE Oncology Integrated Datasets Market Size, by Country/Region, 2019–2029 (USD Million) 
Table 19    RWE Oncology Consulting Services Market Size, by Country/Region, 2019–2029 (USD Million) 
Table 20    Global RWE Oncology Solutions Market Size, by Application, 2019–2029 (USD Million) 
Table 21    Global RWE Oncology Solutions Market Size for Market Access & Reimbursement/Coverage Decisions, by Country/Region, 2019–2029 (USD Million) 
Table 22    Oncology: Drugs in the R&D Pipeline 
Table 23    Global RWE Oncology Solutions Market Size for Drug Development & Approvals, by Country/Region, 2019–2029 (USD Million) 
Table 24    Global RWE Oncology Solutions Market Size for Medical Device Development & Approvals, by Country/Region, 2019–2029 (USD Million) 
Table 25    Global RWE Oncology Solutions Market Size for Post-Market Surveillance, by Country/ Region, 2019–2029 (USD Million) 
Table 26    Global RWE Oncology Solutions Market Size for Other Applications, by Country/Region, 2019–2029 (USD Million) 
Table 27    Global RWE Oncology Solutions Market Size, by End User, 2019–2029 (USD Million) 
Table 28    Global RWE Oncology Solutions Market Size for Pharmaceutical, Biotechnology, and Medical Device Companies, by Country/Region, 2019–2029 (USD Million) 
Table 29    Global RWE Oncology Market Size for Healthcare Payers, by Country/Region, 2019–2029 (USD Million) 
Table 30    Global RWE Oncology Solutions Market Size for Healthcare Providers, by Country/Region, 2019–2029 (USD Million) 
Table 31    Global RWE Oncology Market Size for Other End Users, by Country/Region, 2019–2029 (USD Million) 
Table 32    Global RWE Oncology Solutions Market Size, by Country/Region, 2020–2029 (USD Million) 
Table 33    North America: RWE Oncology Solutions Market Size, by Country, 2020–2029 (USD Million) 
Table 34    North America: RWE Oncology Solutions Market Size, by Component, 2020–2029 (USD Million) 
Table 35    North America: RWE Oncology Datasets Market Size, by Type, 2020–2029 (USD Million) 
Table 36    North America: RWE Oncology Disparate Datasets Market Size, by Type, 2020–2029 (USD Million) 
Table 37    North America: RWE Oncology Solutions Market Size, by Application, 2020–2029 (USD Million) 
Table 38    North America: RWE Oncology Solutions Market Size, by End User, 2020–2029 (USD Million) 
Table 39    U.S.: Estimated Number of New Cancer Cases (2021–2022) 
Table 40    U.S.: RWE Oncology Solutions Market Size, by Component, 2020–2029 (USD Million) 
Table 41    U.S.: RWE Datasets Market Size, by Type, 2020–2029 (USD Million) 
Table 42    U.S.: RWE Disparate Datasets Market Size, by Type, 2020–2029 (USD Million) 
Table 43    U.S.: RWE Oncology Solutions Market Size, by Application, 2020–2029 (USD Million) 
Table 44    U.S.: RWE Solutions Market Size, by End User, 2020–2029 (USD Million) 
Table 45    Canada: RWE Oncology Solutions Market Size, by Component, 2020–2029 (USD Million) 
Table 46    Canada: RWE Datasets Market Size, by Type, 2020–2029 (USD Million) 
Table 47    Canada: RWE Disparate Datasets Market Size, by Type, 2020–2029 (USD Million) 
Table 48    Canada: RWE Oncology Solutions Market Size, by Application, 2020–2029 (USD Million) 
Table 49    Canada: RWE Oncology Market Size, by End User, 2020–2029 (USD Million) 
Table 50    Europe: RWE Oncology Solutions Market Size, by Country, 2019–2029 (USD Million) 
Table 51    Europe: RWE Oncology Solutions Market Size, by Component, 2020–2029 (USD Million) 
Table 52    Europe: RWE Oncology Datasets Market Size, by Type, 2020–2029 (USD Million) 
Table 53    Europe: RWE Oncology Solutions Disparate Datasets Market Size, by Type, 2020–2029 (USD Million) 
Table 54    Europe: RWE Oncology Solutions Market Size, by Application, 2020–2029 (USD Million) 
Table 55    Europe: RWE Oncology Solutions Market Size, by End User, 2020–2029 (USD Million) 
Table 56    U.K.: Conferences and Workshops on Real-world Evidence Solutions 
Table 57    U.K.: RWE Oncology Solutions Market Size, by Component, 2020–2029 (USD Million) 
Table 58    U.K.: RWE Oncology Datasets Market Size, by Type, 2020–2029 (USD Million) 
Table 59    U.K.: RWE Oncology Solutions Disparate Datasets Market Size, by Type, 2020–2029 (USD Million) 
Table 60    U.K.: RWE Oncology Solutions Market Size, by Application, 2020–2029 (USD Million) 
Table 61    U.K.: RWE Oncology Solutions Market Size, by End User, 2020–2029 (USD Million) 
Table 62    Conferences, Symposia, and Workshops in Germany 
Table 63    Germany: RWE Oncology Solutions Market Size, by Component, 2020–2029 (USD Million) 
Table 64    Germany: RWE Oncology Solutions Datasets Market Size, by Type, 2020–2029 (USD Million) 
Table 65    Germany: RWE Oncology Solutions Disparate Datasets Market Size, by Type, 2020–2029 (USD Million) 
Table 66    Germany: RWE Oncology Solutions Market Size, by Application, 2020–2029 (USD Million) 
Table 67    Germany: RWE Oncology Solutions Market Size, by End User, 2020–2029 (USD Million) 
Table 68    France: RWE Oncology Solutions Market Size, by Component, 2020–2029 (USD Million) 
Table 69    France: RWE Oncology Solutions Datasets Market Size, by Type, 2020–2029 (USD Million) 
Table 70    France: RWE Oncology Solutions Disparate Datasets Market Size, by Type, 2020–2029 (USD Million) 
Table 71    France: RWE Oncology Solutions Market Size, by Application, 2020–2029 (USD Million) 
Table 72    France: RWE Oncology Solutions Market Size, by End User, 2020–2029 (USD Million) 
Table 73    Italy: RWE Oncology Solutions Market Size, by Component, 2020–2029 (USD Million) 
Table 74    Italy: RWE Oncology Solutions Datasets Market Size, by Type, 2020–2029 (USD Million) 
Table 75    Italy: RWE Oncology Solutions Disparate Datasets Market Size, by Type, 2020–2029 (USD Million) 
Table 76    Italy: RWE Oncology Market Size, by Application, 2020–2029 (USD Million) 
Table 77    Italy: RWE Oncology Solutions Market Size, by End User, 2020–2029 (USD Million) 
Table 78    Spain: RWE Oncology Market Size, by Component, 2020–2029 (USD Million) 
Table 79    Spain: RWE Oncology Solutions Datasets Market Size, by Type, 2020–2029 (USD Million) 
Table 80    Spain: RWE Oncology Solutions Disparate Datasets Market Size, by Type, 2020–2029 (USD Million) 
Table 81    Spain: RWE Oncology Solutions Market Size, by Application, 2020–2029 (USD Million) 
Table 82    Spain: RWE Oncology Solutions Market Size, by End User, 2020–2029 (USD Million) 
Table 83    RoE: RWE Oncology Solutions Market Size, by Component, 2020–2029 (USD Million) 
Table 84    RoE: RWE Oncology Solutions Datasets Market Size, by Type, 2020–2029 (USD Million) 
Table 85    RoE: RWE Oncology Solutions Disparate Datasets Market Size, by Type, 2020–2029 (USD Million) 
Table 86    RoE: RWE Oncology Solutions Market Size, by Application, 2020–2029 (USD Million) 
Table 87    RoE: RWE Oncology Solutions Market Size, by End User, 2020–2029 (USD Million) 
Table 88    Latin America: RWE Oncology Solutions Market Size, by Component, 2020–2029 (USD Million) 
Table 89    Latin America: RWE Oncology Solutions Datasets Market Size, by Type, 2020–2029 (USD Million) 
Table 90    Latin America: RWE Oncology Solutions Disparate Datasets Market Size, by Type, 2020–2029 (USD Million) 
Table 91    Latin America: RWE Oncology Solutions Market Size, by Application, 2020–2029 (USD Million) 
Table 92    Latin America: RWE Oncology Solutions Market Size, by End User, 2020–2029 (USD Million) 
Table 93    Middle East & Africa: RWE Oncology Solutions Market Size, by Component, 2020–2029 (USD Million) 
Table 94     Middle East & Africa: RWE Oncology Solutions Datasets Market Size, by Type, 2020–2029 (USD Million) 
Table 95    Middle East & Africa: RWE Oncology Solutions Disparate Datasets Market Size, by Type, 2020–2029 (USD Million) 
Table 96    Middle East & Africa: RWE Oncology Solutions Market Size, by Application, 2020–2029 (USD Million) 
Table 97    Middle East & Africa: RWE Oncology Solutions Market Size, by End User, 2020–2029 (USD Million) 
Table 98    Recent Developments, by Company, 2018–2021 

LIST OF FIGURES

Figure 1    Key Stakeholders 
Figure 2    Research Process 
Figure 3    Key Secondary Sources 
Figure 4    Primary Research Techniques
Figure 5    Key Executives Interviewed 
Figure 6    Breakdown of Primary Interviews (Supply-side & Demand-Side) 
Figure 7    Market Size Estimation
Figure 8    Global RWE Oncology Solutions Market, by Component, 2022 Vs. 2029 (USD Million) 
Figure 9    Global RWE Oncology Solutions Market, by Application, 2022 Vs. 2029 (USD Million) 
Figure 10    Global RWE Oncology Solutions Market, by End User, 2022 Vs. 2029 (USD Million) 
Figure 11    RWE Oncology Solutions Market, by Geography 
Figure 12    Market Dynamics 
Figure 13    Number of People with Chronic Conditions in the U.S. (2000-2030) 
Figure 14    Percentage of Personalized Medicines Approved (2015-2020) 
Figure 15    Asia-Pacific: Percent Share of Global Clinical Trial Activity (2012-2020) 
Figure 16    Global RWE Oncology Solutions Market Size, by Component, 2022–2029 (USD Million) 
Figure 17    U.S.: Number of E-Prescriptions, 2013–2020 (Billions) 
Figure 18    Global RWE Oncology Solutions Market Size, by Application, 2022–2029 (USD Million) 
Figure 19    Estimated Number of New Cancer Cases, by Region, 2020–2040 (In Millions) 
Figure 20    Global RWE Oncology Solutions Market Size, by End User, 2022–2029 (USD Million) 
Figure 21    Proportion of the Pharmaceutical Pipeline Which is in Development for Cancer, 2010–2021 
Figure 22    Global RWE Oncology Solutions Market, by Region, 2022–2029 (USD Million) 
Figure 23    North America: RWE Oncology Solutions Market Snapshot 
Figure 24    Europe: RWE Oncology Solutions Market Snapshot 
Figure 25    France: Share of Population Aged 65 & Above, 2010–2020 
Figure 26    Italy: Share of Population Aged 65 Years & Above, 2015–2020 
Figure 27    Key Growth Strategies Adopted by Leading Players (2018–2021) 
Figure 28    Real-world Evidence Oncology Solutions: Competitive Benchmarking 
Figure 29    Market Share Analysis: Real-world Evidence Oncology Solutions Industry (2021) 
Figure 30    IQVIA HOLDINGS INC.: Financial Overview
Figure 31    PPD, Inc.: Financial Overview
Figure 32    ICON plc: Financial Overview
Figure 33    IBM corporation: Financial Overview
Figure 34    UnitedHealth Group Incorporated: Financial Overview
Figure 35    Oracle Corporation: Financial Overview
Figure 36    Anthem, Inc.: Financial Overview
Figure 37    Clinigen Group plc: Financial Overview
Figure 38    Cognizant Technology Solutions Corporation: Financial Overview
Figure 39    PerkinElmer, Inc.: Financial Overview

  Request Sample

1.    Introduction 
       1.1.    Market Definition 
       1.2.    Market Ecosystem 
       1.3.    Currency 

2.    Research Methodology 
       2.1.    Research Process 
       2.2.    Data Collection & Validation 
                 2.2.1.    Secondary Research 
                 2.2.2.    Primary Research 
       2.3.    Market Assessment 
                 2.3.1.    Market Size Estimation 
                              2.3.1.1.    Bottom-up Approach 
                              2.3.1.2.    Top-down Approach
                              2.3.1.3.    Growth Forecast
                 2.3.2.    Market Share Analysis

3.    Executive Summary 

4.    Market Insights 
       4.1.    Market Overview 
       4.2.    Drivers 
                 4.2.1.    Growing Burden of Cancer
                 4.2.2.    Rising Focus Towards Personalized Healthcare 
                 4.2.3.    Delays in Drug Development and the Subsequent Increase in Development Costs 
                 4.2.4.    Shift Towards Value-based Care 
                 4.2.5.    Rapidly Growing Big Data in Healthcare 
       4.3.    Restraints 
                 4.3.1.    Reluctance to Rely on Real-world Studies 
       4.4.    Opportunities 
                 4.4.1.    Emerging Economies 
                 4.4.2.    Rising Focus on End-to-end RWE Services 
                 4.4.3.    Rising Adoption of Wearable Devices, Mobile Apps, and Artificial Intelligence in RWE 
       4.5.    Challenges 
                 4.5.1.    Lack of Standardized Methodologies to Develop RWE 
       4.6.    Impact Assessment of COVID-19 
       4.7.    Key Market Trends 
                 4.7.1.    Growing Adoption of RWE in Drug Development and Commercialization 
                 4.7.2.    Rising Number of Consolidations 
                 4.7.3.    Improved Patient Outcomes and value Creation from Real-world Evidence 

5.   Regulatory Analysis— Real-world Evidence (RWE) Oncology Solutions Market 
      5.1.    Introduction 
      5.2.    North America 
      5.3.    Europe 
      5.4.    Asia-Pacific 
      5.5.    Rest of the World 

6.   Pricing Models (EMR/Genomic/Integrated Datasets) 
      6.1.    Introduction 
      6.2.    Pay Per Patient Record (Volume-based Pricing) 
      6.3.    Pay Per Usage (Value-based Pricing) 
      6.4.    Annual Subscription 

7.   Global RWE Oncology Solutions Market, by Component 
      7.1.    Introduction 
      7.2.    Datasets 
                 7.2.1.    Disparate Datasets 
                              7.2.1.1.    EMR/EHR/Clinical Data 
                              7.2.1.2.    Claims & Billing Data 
                              7.2.1.3.    Pharmacy Data 
                              7.2.1.4.    Cancer Registries 
                              7.2.1.5.    Other Disparate Datasets 
                 7.2.2.    Integrated Datasets 
       7.3.    Consulting Services 

8.   Global RWE Oncology Solutions Market, by Application 
      8.1.    Introduction
      8.2.    Drug Development & Approvals
      8.3.    Market Access & Reimbursement/Coverage Decisions  
      8.4.    Medical Device Development & Approvals 
      8.5.    Post-market Surveillance 
      8.6.    Other Applications 

9.   Global RWE Oncology Solutions Market, by End User 
      9.1.    Introduction 
      9.2.    Pharmaceutical, Biotechnology, and Medical Device Companies 
      9.3.    Healthcare Payers 
      9.4.    Healthcare Providers 
      9.5.    Other End Users 

10.   RWE Oncology Solutions Market, by Geography 
        10.1.    Introduction 
        10.2.    North America
                   10.2.1.    U.S. 
                   10.2.2.    Canada 
        10.3.    Europe 
                   10.3.1.    U.K. 
                   10.3.2.    Germany 
                   10.3.3.    France 
                   10.3.4.    Italy 
                   10.3.5.    Spain 
        10.4.    Asia-Pacific 
                   10.4.1.    Japan 
                   10.4.2.    China 
                   10.4.3.    India 
                   10.4.4.    South Korea 
                   10.4.5.    Taiwan 
                   10.4.6.    Singapore 
                   10.4.7.    Rest of Asia-Pacific 
        10.5.    Latin America 
        10.6.    Middle East & Africa 

11.   Competitive Landscape     
        11.1.    Introduction 
        11.2.    Key Growth Strategies 
        11.3.    Competitive Benchmarking 
        11.4.    Market Share Analysis (2020) 
                   11.4.1.    IQVIA Holdings, Inc. (U.S.) 
                   11.4.2.    ICON plc (Ireland) 
                   11.4.3.    PPD, Inc. 

12.   Company Profiles 
        12.1.    IQVIA HOLDINGS INC. 
        12.2.    PPD, Inc. 
        12.3.    ICON plc 
        12.4.    Parexel International Corporation 
        12.5.    IBM CORPORATION 
        12.6.    UnitedHealth Group Incorporated 
        12.7.    Flatiron Health 
        12.8.    ORACLE CORPORATION 
        12.9.    SAS Institute, Inc. 
        12.10.    Anthem, Inc. 
        12.11.    Clinigen Group plc 
        12.12.    Cognizant Technology Solutions Corporation 
        12.13.    PerkinElmer, Inc. 

13.   Appendix 
        13.1.    Questionnaire 
        13.2.    Available Customization

LIST OF TABLES

Table 1    Global RWE Oncology Solutions Market Drivers: Impact Analysis (2021–2028) 
Table 2    Number of Persons Aged 65 Years or Over, by Region (2019 Vs. 2050) 
Table 3    Total Per-study Cost (In USD Million), by Phase and Therapeutic Area 
Table 4    Sources of Healthcare Data 
Table 5    Global RWE Oncology Market Restraints: Impact Analysis (2021–2028) 
Table 6    RWE in Latin American Countries 
Table 7    Observed Indicative Prices of Real-World Data by Type (USD Per Patient Record) 
Table 8    Global RWE Oncology Solutions Market Size, by Component, 2019–2029 (USD Million) 
Table 9    Global Real-world Evidence Oncology Datasets Market Size, by Type, 2019–2029 (USD Million) 
Table 10    Real-world Evidence Oncology Datasets Market Size, by Country/Region, 2019–2029 (USD Million) 
Table 11    Global RWE Oncology Disparate Datasets Market Size, by Type, 2019–2029 (USD Million) 
Table 12    RWE Oncology Disparate Datasets Market Size, by Country/Region, 2019–2029 (USD Million) 
Table 13    RWE Oncology EMR/EHR/Clinical Data Market Size, by Country/Region, 2019–2029 (USD Million) 
Table 14    RWE Oncology Claims & Billing Data Market Size, by Country/Region, 2019–2029 (USD Million) 
Table 15    RWE Oncology Pharmacy Data Market Size, by Country/Region, 2019–2029 (USD Million) 
Table 16    RWE Cancer Registries Data Market Size, by Country/Region, 2019–2029 (USD Million) 
Table 17    Other RWE Oncology Disparate Datasets Market Size, by Country/Region, 2019–2029 (USD Million) 
Table 18    RWE Oncology Integrated Datasets Market Size, by Country/Region, 2019–2029 (USD Million) 
Table 19    RWE Oncology Consulting Services Market Size, by Country/Region, 2019–2029 (USD Million) 
Table 20    Global RWE Oncology Solutions Market Size, by Application, 2019–2029 (USD Million) 
Table 21    Global RWE Oncology Solutions Market Size for Market Access & Reimbursement/Coverage Decisions, by Country/Region, 2019–2029 (USD Million) 
Table 22    Oncology: Drugs in the R&D Pipeline 
Table 23    Global RWE Oncology Solutions Market Size for Drug Development & Approvals, by Country/Region, 2019–2029 (USD Million) 
Table 24    Global RWE Oncology Solutions Market Size for Medical Device Development & Approvals, by Country/Region, 2019–2029 (USD Million) 
Table 25    Global RWE Oncology Solutions Market Size for Post-Market Surveillance, by Country/ Region, 2019–2029 (USD Million) 
Table 26    Global RWE Oncology Solutions Market Size for Other Applications, by Country/Region, 2019–2029 (USD Million) 
Table 27    Global RWE Oncology Solutions Market Size, by End User, 2019–2029 (USD Million) 
Table 28    Global RWE Oncology Solutions Market Size for Pharmaceutical, Biotechnology, and Medical Device Companies, by Country/Region, 2019–2029 (USD Million) 
Table 29    Global RWE Oncology Market Size for Healthcare Payers, by Country/Region, 2019–2029 (USD Million) 
Table 30    Global RWE Oncology Solutions Market Size for Healthcare Providers, by Country/Region, 2019–2029 (USD Million) 
Table 31    Global RWE Oncology Market Size for Other End Users, by Country/Region, 2019–2029 (USD Million) 
Table 32    Global RWE Oncology Solutions Market Size, by Country/Region, 2020–2029 (USD Million) 
Table 33    North America: RWE Oncology Solutions Market Size, by Country, 2020–2029 (USD Million) 
Table 34    North America: RWE Oncology Solutions Market Size, by Component, 2020–2029 (USD Million) 
Table 35    North America: RWE Oncology Datasets Market Size, by Type, 2020–2029 (USD Million) 
Table 36    North America: RWE Oncology Disparate Datasets Market Size, by Type, 2020–2029 (USD Million) 
Table 37    North America: RWE Oncology Solutions Market Size, by Application, 2020–2029 (USD Million) 
Table 38    North America: RWE Oncology Solutions Market Size, by End User, 2020–2029 (USD Million) 
Table 39    U.S.: Estimated Number of New Cancer Cases (2021–2022) 
Table 40    U.S.: RWE Oncology Solutions Market Size, by Component, 2020–2029 (USD Million) 
Table 41    U.S.: RWE Datasets Market Size, by Type, 2020–2029 (USD Million) 
Table 42    U.S.: RWE Disparate Datasets Market Size, by Type, 2020–2029 (USD Million) 
Table 43    U.S.: RWE Oncology Solutions Market Size, by Application, 2020–2029 (USD Million) 
Table 44    U.S.: RWE Solutions Market Size, by End User, 2020–2029 (USD Million) 
Table 45    Canada: RWE Oncology Solutions Market Size, by Component, 2020–2029 (USD Million) 
Table 46    Canada: RWE Datasets Market Size, by Type, 2020–2029 (USD Million) 
Table 47    Canada: RWE Disparate Datasets Market Size, by Type, 2020–2029 (USD Million) 
Table 48    Canada: RWE Oncology Solutions Market Size, by Application, 2020–2029 (USD Million) 
Table 49    Canada: RWE Oncology Market Size, by End User, 2020–2029 (USD Million) 
Table 50    Europe: RWE Oncology Solutions Market Size, by Country, 2019–2029 (USD Million) 
Table 51    Europe: RWE Oncology Solutions Market Size, by Component, 2020–2029 (USD Million) 
Table 52    Europe: RWE Oncology Datasets Market Size, by Type, 2020–2029 (USD Million) 
Table 53    Europe: RWE Oncology Solutions Disparate Datasets Market Size, by Type, 2020–2029 (USD Million) 
Table 54    Europe: RWE Oncology Solutions Market Size, by Application, 2020–2029 (USD Million) 
Table 55    Europe: RWE Oncology Solutions Market Size, by End User, 2020–2029 (USD Million) 
Table 56    U.K.: Conferences and Workshops on Real-world Evidence Solutions 
Table 57    U.K.: RWE Oncology Solutions Market Size, by Component, 2020–2029 (USD Million) 
Table 58    U.K.: RWE Oncology Datasets Market Size, by Type, 2020–2029 (USD Million) 
Table 59    U.K.: RWE Oncology Solutions Disparate Datasets Market Size, by Type, 2020–2029 (USD Million) 
Table 60    U.K.: RWE Oncology Solutions Market Size, by Application, 2020–2029 (USD Million) 
Table 61    U.K.: RWE Oncology Solutions Market Size, by End User, 2020–2029 (USD Million) 
Table 62    Conferences, Symposia, and Workshops in Germany 
Table 63    Germany: RWE Oncology Solutions Market Size, by Component, 2020–2029 (USD Million) 
Table 64    Germany: RWE Oncology Solutions Datasets Market Size, by Type, 2020–2029 (USD Million) 
Table 65    Germany: RWE Oncology Solutions Disparate Datasets Market Size, by Type, 2020–2029 (USD Million) 
Table 66    Germany: RWE Oncology Solutions Market Size, by Application, 2020–2029 (USD Million) 
Table 67    Germany: RWE Oncology Solutions Market Size, by End User, 2020–2029 (USD Million) 
Table 68    France: RWE Oncology Solutions Market Size, by Component, 2020–2029 (USD Million) 
Table 69    France: RWE Oncology Solutions Datasets Market Size, by Type, 2020–2029 (USD Million) 
Table 70    France: RWE Oncology Solutions Disparate Datasets Market Size, by Type, 2020–2029 (USD Million) 
Table 71    France: RWE Oncology Solutions Market Size, by Application, 2020–2029 (USD Million) 
Table 72    France: RWE Oncology Solutions Market Size, by End User, 2020–2029 (USD Million) 
Table 73    Italy: RWE Oncology Solutions Market Size, by Component, 2020–2029 (USD Million) 
Table 74    Italy: RWE Oncology Solutions Datasets Market Size, by Type, 2020–2029 (USD Million) 
Table 75    Italy: RWE Oncology Solutions Disparate Datasets Market Size, by Type, 2020–2029 (USD Million) 
Table 76    Italy: RWE Oncology Market Size, by Application, 2020–2029 (USD Million) 
Table 77    Italy: RWE Oncology Solutions Market Size, by End User, 2020–2029 (USD Million) 
Table 78    Spain: RWE Oncology Market Size, by Component, 2020–2029 (USD Million) 
Table 79    Spain: RWE Oncology Solutions Datasets Market Size, by Type, 2020–2029 (USD Million) 
Table 80    Spain: RWE Oncology Solutions Disparate Datasets Market Size, by Type, 2020–2029 (USD Million) 
Table 81    Spain: RWE Oncology Solutions Market Size, by Application, 2020–2029 (USD Million) 
Table 82    Spain: RWE Oncology Solutions Market Size, by End User, 2020–2029 (USD Million) 
Table 83    RoE: RWE Oncology Solutions Market Size, by Component, 2020–2029 (USD Million) 
Table 84    RoE: RWE Oncology Solutions Datasets Market Size, by Type, 2020–2029 (USD Million) 
Table 85    RoE: RWE Oncology Solutions Disparate Datasets Market Size, by Type, 2020–2029 (USD Million) 
Table 86    RoE: RWE Oncology Solutions Market Size, by Application, 2020–2029 (USD Million) 
Table 87    RoE: RWE Oncology Solutions Market Size, by End User, 2020–2029 (USD Million) 
Table 88    Latin America: RWE Oncology Solutions Market Size, by Component, 2020–2029 (USD Million) 
Table 89    Latin America: RWE Oncology Solutions Datasets Market Size, by Type, 2020–2029 (USD Million) 
Table 90    Latin America: RWE Oncology Solutions Disparate Datasets Market Size, by Type, 2020–2029 (USD Million) 
Table 91    Latin America: RWE Oncology Solutions Market Size, by Application, 2020–2029 (USD Million) 
Table 92    Latin America: RWE Oncology Solutions Market Size, by End User, 2020–2029 (USD Million) 
Table 93    Middle East & Africa: RWE Oncology Solutions Market Size, by Component, 2020–2029 (USD Million) 
Table 94     Middle East & Africa: RWE Oncology Solutions Datasets Market Size, by Type, 2020–2029 (USD Million) 
Table 95    Middle East & Africa: RWE Oncology Solutions Disparate Datasets Market Size, by Type, 2020–2029 (USD Million) 
Table 96    Middle East & Africa: RWE Oncology Solutions Market Size, by Application, 2020–2029 (USD Million) 
Table 97    Middle East & Africa: RWE Oncology Solutions Market Size, by End User, 2020–2029 (USD Million) 
Table 98    Recent Developments, by Company, 2018–2021 

LIST OF FIGURES

Figure 1    Key Stakeholders 
Figure 2    Research Process 
Figure 3    Key Secondary Sources 
Figure 4    Primary Research Techniques
Figure 5    Key Executives Interviewed 
Figure 6    Breakdown of Primary Interviews (Supply-side & Demand-Side) 
Figure 7    Market Size Estimation
Figure 8    Global RWE Oncology Solutions Market, by Component, 2022 Vs. 2029 (USD Million) 
Figure 9    Global RWE Oncology Solutions Market, by Application, 2022 Vs. 2029 (USD Million) 
Figure 10    Global RWE Oncology Solutions Market, by End User, 2022 Vs. 2029 (USD Million) 
Figure 11    RWE Oncology Solutions Market, by Geography 
Figure 12    Market Dynamics 
Figure 13    Number of People with Chronic Conditions in the U.S. (2000-2030) 
Figure 14    Percentage of Personalized Medicines Approved (2015-2020) 
Figure 15    Asia-Pacific: Percent Share of Global Clinical Trial Activity (2012-2020) 
Figure 16    Global RWE Oncology Solutions Market Size, by Component, 2022–2029 (USD Million) 
Figure 17    U.S.: Number of E-Prescriptions, 2013–2020 (Billions) 
Figure 18    Global RWE Oncology Solutions Market Size, by Application, 2022–2029 (USD Million) 
Figure 19    Estimated Number of New Cancer Cases, by Region, 2020–2040 (In Millions) 
Figure 20    Global RWE Oncology Solutions Market Size, by End User, 2022–2029 (USD Million) 
Figure 21    Proportion of the Pharmaceutical Pipeline Which is in Development for Cancer, 2010–2021 
Figure 22    Global RWE Oncology Solutions Market, by Region, 2022–2029 (USD Million) 
Figure 23    North America: RWE Oncology Solutions Market Snapshot 
Figure 24    Europe: RWE Oncology Solutions Market Snapshot 
Figure 25    France: Share of Population Aged 65 & Above, 2010–2020 
Figure 26    Italy: Share of Population Aged 65 Years & Above, 2015–2020 
Figure 27    Key Growth Strategies Adopted by Leading Players (2018–2021) 
Figure 28    Real-world Evidence Oncology Solutions: Competitive Benchmarking 
Figure 29    Market Share Analysis: Real-world Evidence Oncology Solutions Industry (2021) 
Figure 30    IQVIA HOLDINGS INC.: Financial Overview
Figure 31    PPD, Inc.: Financial Overview
Figure 32    ICON plc: Financial Overview
Figure 33    IBM corporation: Financial Overview
Figure 34    UnitedHealth Group Incorporated: Financial Overview
Figure 35    Oracle Corporation: Financial Overview
Figure 36    Anthem, Inc.: Financial Overview
Figure 37    Clinigen Group plc: Financial Overview
Figure 38    Cognizant Technology Solutions Corporation: Financial Overview
Figure 39    PerkinElmer, Inc.: Financial Overview

  Request Sample
Related Research